Insmed Incorporated is a global biopharmaceutical company focused on serious and rare diseases, with a core emphasis on respiratory and inflammatory conditions. Its commercial portfolio is anchored by BRINSUPRI (brensocatib), a once-daily oral DPP1 inhibitor approved for non-cystic fibrosis bronchiectasis (NCFB) in the United States, Europe, and Japan, and ARIKAYCE (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease. The pipeline includes TPIP (treprostinil palmitil inhalation powder), an investigational therapy in development for pulmonary arterial hypertension and related conditions, alongside earlier-stage respiratory and immunology programs. Investors follow INSM for its blockbuster revenue trajectory and the optionality of its pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, INSM advanced approximately 53.6%, climbing from a closing price of $94.04 on October 21 to $144.46 at the November 19 close. The move was punctuated by two sharp upswings: a strong rally following third-quarter earnings and a single-session surge on the Sanofi acquisition report. I also reviewed patterns with Tickeron’s AI Pattern Search Engine to confirm the momentum signals.
The trailing quarter tells a more volatile story. Three months ago, shares traded around $125, but they slid to a late-October low near $93 before rebounding sharply. As a result, INSM ended the quarter up roughly 15%, with most of that gain concentrated in the final weeks of the period.
Two verified catalysts powered the 30-day advance. First, on October 29, Insmed reported third-quarter 2026 results showing total revenue of $524.4 million, up 268% year over year, while BRINSUPRI global revenue grew 29% quarter over quarter. The company narrowed its operating loss to $89.4 million from $366.0 million a year earlier and raised its full-year BRINSUPRI revenue guidance to a range of $1.35 billion to $1.4 billion, up from the prior low end of $1.25 billion.
Second, on November 19, Bloomberg reported that Sanofi was weighing an acquisition of Insmed, citing people familiar with the matter. The report noted the transaction could rank among the largest biopharma deals in recent years, with INSM's market value around $26 billion. Shares closed up 20.58% that day, with intraday gains exceeding 23%. Analysts, including Mizuho's Graig Suvannavejh, characterized Insmed as a long-standing takeover target and maintained constructive ratings and price targets on the stock.
The quarterly trend reflects a broader narrative of commercial execution against a backdrop of earlier valuation pressure. Through much of 2026, INSM traded below its prior highs even as BRINSUPRI ramped toward blockbuster status, and management reiterated peak-revenue expectations of more than $7 billion for BRINSUPRI, more than $6 billion for TPIP, and more than $1 billion for ARIKAYCE. The October launch of BRINSUPRI in Japan added another growth leg, while renewed merger-and-acquisition speculation refocused investor attention on Insmed's strategic value within the respiratory rare-disease market.
Looking ahead, investors are likely to monitor the continued commercial ramp of BRINSUPRI in the United States and Japan, updates to full-year revenue guidance, and pipeline milestones such as TPIP clinical readouts. The reported Sanofi discussions remain unresolved, with no guarantee a deal is completed and the possibility that other bidders could emerge, so developments around any transaction will remain a key swing factor. Broader sector dynamics, including biotech M&A activity, interest-rate expectations, and sentiment toward high-growth rare-disease companies, may also influence the stock. Investors should weigh these factors against Insmed's execution and pipeline progress rather than relying on any single catalyst.
In my own analysis, I frequently review Tickeron’s Trending AI Robots page to compare top-performing automated strategies across different market conditions. The section highlights curated bots from a wider universe, showing variations in approach, holding periods, and results, which helps me evaluate options that align with my research without depending on any single method.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 69 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
INSM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INSM crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 202 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
INSM broke above its upper Bollinger Band on November 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.982) is normal, around the industry mean (3.596). P/E Ratio (-27.768) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company
Industry Biotechnology